ADIM
KYNB

Alpha DNA Investment Management’s Kyntra Bio KYNB Stock Holding History

Alpha DNA Investment Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1
Closed – – 293
2021
Q1 		$0 Hold
1
– – ﹤0.01% 720
2020
Q4 		$0 Buy
+1
New +$1.05K ﹤0.01% 603

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alpha DNA Investment Management's KYNB Position: Q2 2021 in Review

Alpha DNA Investment Management sold out of Kyntra Bio (KYNB) in Q2 2021, closing a stake of 1 share.

Alpha DNA Investment Management first reported a position in KYNB in Q4 2020 and held it in 2 quarters. The position peaked at $0 in Q1 2021. 174 funds tracked by Wall St. Rank hold KYNB as of Q2 2021.

  • Alpha DNA Investment Management reported no remaining Kyntra Bio position as of Q2 2021 after selling out during the quarter.
  • Alpha DNA Investment Management sold 1 Kyntra Bio share in Q2 2021.
  • Alpha DNA Investment Management first reported a position in Kyntra Bio in Q4 2020 and held it in 2 quarters.
  • Alpha DNA Investment Management's Kyntra Bio position peaked at $0 in Q1 2021.
  • 174 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2021.

Based on Alpha DNA Investment Management's 13F filing for Q2 2021, filed 10 Aug 2021.